I don't understand the logic behind the data set DESeq provides when I perform the differential expression command. All of the numbers in the columns are in random order, there is not one column that gives the table numerical sense. What is the basis for the list of genes I am recieving? Fold change on the other hand makes more sense be it up or down regulation and the numbers in the columns have an obvious order. Is the fold change shown relative to each other, or in the perspective of the first condition over the second?
Unconfigured Ad
Collapse
X
-
-
The first column is just a row id taken from your input file. The data is simply presented in the same order as the input data. If you don't want to sort the data in R, just write it out to a tab delimited table and parse it in Excel (the headers will be offset by one, since that first column is not data, it's just row number relative to the input data order).
> res <- nbinomTest(cds, "Control", "Treatment")
> write.table(res, file = "nBinom_results.txt", sep = "\t")
Open nBinom_results.txt in Excel and parse it by tabs and sort it by whichever column is of interest. If set up as above, fold change will be for Treatment relative to control (ie. + is up-regulated in Treatement, and - is down-regulated in Treatment.Michael Black, Ph.D.
ScitoVation LLC. RTP, N.C.
-
Thanks For the quick reply Mr. Black
Ok, I understand that the data can be sorted manually in excel, but I don't see what corelation is among the genes that are marked as differential expressed. I would assume it would be greatest to least or vice versa for at least one column of numbers but i am not seeing that relation. I'm sure its there...its just not immediately obvious.
P.S. please excuse my spelling errors I cannot spell well and this Mac wont let me use spell check or rather i don't care enough to make it work or learn how.
Comment
-
The default is to list the data in the same gene/transcript order as the input data. The only way to get order like you wish is to sort the data yourself, by pValue, adjPvalue, fold change, whatever you wish. But the default is just to list it by input order.
Note too that if you use the two commands I wrote, you get the results back for all the genes in your input, not just significant genes. You would then have to sort that table and apply whatever statistical cutoffs you wish (e.g. sort by adjPvalue, then select only those less than 0.01).
You could do something like:
> resSig <- res[ res$padj < 0.1, ]
> head(resSig[ order(resSig$padj), ])
to see the most significant genes sorted by adjPvalue. But again, if you wrote those out to a file:
> write.table(resSig, file = "nBinom_results_lessthan_.1.txt", sep = "\t")
That file would only include those genes with an adjPvalue less than 0.1, but the table would still be sorted initially simply by the row input order of the genes. So, you would still need to sort it manually to apply whatever order you wished to see in it.Michael Black, Ph.D.
ScitoVation LLC. RTP, N.C.
Comment
Latest Articles
Collapse
-
by SEQadmin2
CRISPR/Cas9 sparked the gene editing revolution for both research and therapeutics.1 But this system still showed severe issues that limited its applications. The most prominent were the heavy reliance on PAM sequences, delivery limitations, double-stranded breaks that prompt unintended edits and cell death, and editing inefficiency (both in targeting and in knock-in reliability).
Despite this, “CRISPR helped turn genome editing from a specialized technique into...-
Channel: Articles
07-31-2026, 11:01 AM -
-
by SEQadmin2
Proteomics platforms are evolving rapidly, with advances in mass spectrometry and affinity-based approaches expanding what researchers can detect and at what scale. As the field moves toward deeper proteome coverage and clinical applications, scientists face an increasingly complex landscape of tools. This article will explore how researchers are navigating these choices to find the right platform for their work.
The systematic characterization of the human proteome has...-
Channel: Articles
07-20-2026, 11:48 AM -
-
by SEQadmin2
Genomics studies in neuroscience face a special challenge due to the brain’s complexity and scarcity of samples. Mapping changes in cell type and state using conventional next-generation sequencing methods remains challenging. Advances in technologies like single-cell sequencing, spatial transcriptomics, and long-read sequencing have opened the door to deeper studies of the brain and diseases like Alzheimer’s, amyotrophic lateral sclerosis (ALS), and schizophrenia.
...-
Channel: Articles
07-09-2026, 11:10 AM -
ad_right_rmr
Collapse
News
Collapse
| Topics | Statistics | Last Post | ||
|---|---|---|---|---|
|
Started by SEQadmin2, Yesterday, 07:41 AM
|
0 responses
12 views
0 reactions
|
Last Post
by SEQadmin2
Yesterday, 07:41 AM
|
||
|
Started by SEQadmin2, 08-03-2026, 10:13 AM
|
0 responses
26 views
0 reactions
|
Last Post
by SEQadmin2
08-03-2026, 10:13 AM
|
||
|
Started by SEQadmin2, 07-31-2026, 02:55 AM
|
0 responses
39 views
0 reactions
|
Last Post
by SEQadmin2
07-31-2026, 02:55 AM
|
||
|
Started by SEQadmin2, 07-24-2026, 12:17 PM
|
0 responses
25 views
0 reactions
|
Last Post
by SEQadmin2
07-24-2026, 12:17 PM
|
Comment